

PRESS RELEASE

**Alfasigma Reports Record Growth in First-Ever Financial Results;
€1.87 billion Revenue Setting the Stage for Future Growth**

- Revenues grew 37% YoY to €1.87 billion, driven by strong organic performance of key strategic legacy brands (~€150 million revenue growth in absolute value) and the successful integration of recent acquisitions across Alfasigma's portfolio.
- Strong sales, a favourable product mix, and disciplined cost optimization efforts resulted in a 23% YoY increase in adjusted EBITDA to €427 million¹.
- Strategic acquisitions significantly enhance capabilities in specialty and rare diseases, and expanded commercial platform in Western Europe and the US.
- Solid global growth, notably in China, Eastern Europe the US, and Western Europe.

Bologna/Milan, April 1st, 2025 – Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2024, reflecting a pivotal year of strategic transformation and significant growth. In 2024, Alfasigma further redefined its ambition and growth path through successful M&A strategy shifting toward rare diseases and specialty care, while simultaneously bringing its legacy portfolio, including its consumer health brands, to enhance their potential. The Company's recent strategic acquisitions have not only accelerated its international expansion but also significantly enriched and strengthened its pipeline, broadening its portfolio in critical therapeutic areas and adding promising new drug candidates.

Chairman Stefano Golinelli stated, “2024 was a transformational year for Alfasigma as we delivered remarkable growth, driven by our strategic acquisitions and the robust performance of our key therapeutic areas. Our strategic shift, reinforced by targeted acquisitions, innovation-driven pipeline, and strengthened international presence, has set the stage for sustained momentum and exceptional value creation for all stakeholders. I am proud of what we have achieved and excited that we are improving quality of life of even more people across the world”.

Alfasigma's revenues grew 37% YoY to €1.87 billion on the back of both solid organic growth and the successful integration of strategic acquisitions across its portfolio, positioning the Company on track to become a truly global innovative rare disease healthcare company focused on GI and hepatology. Meanwhile, the Company's adjusted EBITDA increased by 23% YoY to €427 million in FY2024 driven by strong sales, a favourable product mix, and disciplined cost optimization efforts.

CEO Francesco Balestrieri commented, “Our exceptional financial results in 2024 clearly validate Alfasigma's strategic direction, highlighting the strength of our expanding product portfolio, particularly across our recent acquisitions of high-margin specialty products like Jyseleca® and Ocaliva®, as well as our enhanced capabilities. As we look to the future, our commitment to innovation, disciplined growth, and operational excellence positions us uniquely to sustain momentum, create enduring value, and involve more stakeholders in our continuing journey of growth and positive patient impact.”

¹Adjusted EBITDA Adjusted EBITDA excludes the impact of restructuring costs and selected items related to Jyseleca® business acquisition

The Company's growth was underpinned by outstanding performances across several strategic product categories, notably in specialty gastroenterology and rare-disease therapeutics. The gastroenterology segment, including products such as Jyseleca® (filgotinib is approved for the treatment of moderate to severe active Rheumatoid Arthritis and Ulcerative Colitis in the EU, UK and Japan)², achieved remarkable year-on-year growth, reinforcing Alfasigma's market leadership and specialty care capabilities. Ocaliva® (obeticholic acid is approved for the treatment of Primary Biliary Cholangitis in the US)³, another recent acquisition, delivered strong performance in hepatology. Both Jyseleca® and Ocaliva® contributed significantly to the company growth, particularly in Western Europe and the U.S.

Moreover, Alfasigma's growth in 2024 was notably driven by impressive performances across strategic international markets. China and Eastern Europe, each delivered outstanding growth, affirming the effectiveness of Alfasigma's targeted geographical strategy. Additionally, markets like the US, Italy, and Western Europe performed strongly, underpinned by the continued success of core therapeutic offerings and newly integrated acquisitions.

Alfasigma's strategic acquisitions have significantly enriched and strengthened our pipeline, enabling us to accelerate the development of key therapies and expand our portfolio in critical therapeutic areas.

Looking ahead, Alfasigma is well-positioned to sustain its dynamic growth trajectory by leveraging its strong product portfolio, pipeline, strategic market presence, and remains strategically focused on maximizing the potential of its established portfolio, accelerating its innovation pipeline, and pursuing further strategic acquisitions in specialty and rare-disease areas. Moreover, the company remains focused on identifying further strategic growth opportunities, advancing innovative R&D, and maintaining operational excellence to enhance patient outcomes and solidify its global leadership position.

-END-

About Alfasigma

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered (in Bologna and Milan). The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. It has offices in many countries, including Italy, the US, Spain, Germany, Mexico, and China; production sites in Italy (Pomezia, RM; Alanno, PE; Sermoneta, LT; Trezzano Rosa, MI), Spain (Tortosa, Baix Ebre), and the United States (Shreveport, Louisiana); and R&D labs in Italy (Pomezia and Bergamo). Alfasigma employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products, contributing to its mission to provide better health and a better quality of life for patients, caregivers, and healthcare providers. It focuses on three main therapeutic areas: Gastroenterology, Vascular, and Rheumatology. Its portfolio spans from primary care to specialty care, rare disease medications, and consumer health products, including medical foods and nutraceuticals. The Group's 2024 revenues reached €1.87B.

Contact Press Office: iCorporate

Luca Bolzoni 3476498627 luca.bolzoni@icorporate.it

²Jyseleca® [Jyseleca, INN-filgotinib; Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4 | Modern Rheumatology | Oxford Academic](#)

³Ocaliva® (obeticholic acid) [[Full Prescribing Information](#)]. Intercept Pharmaceuticals, Inc. Morristown, NJ.